Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEO 134310 in chronic plaque psoriasis
NCT03669757Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Sep 2018
- Primary completion
- Feb 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of LEO 134310 in psoriasis (6 arms), sponsored by LEO Pharma. Primary endpoints: Treatment-Emergent Adverse Events, Treatment-Emergent Application Site Reactions and 4 more. Started Sep 2018; status: completed.
02
Drugs
LEO 134310
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03669757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03669757.